The company is developing DYN101, an investigational antisense medicine designed to reduce the expression of dynamin 2 protein for the treatment of Centronuclear Myopathies, and has a complementary research portfolio targeting other orphan disorders, including its DYN201 program for the treatment of Hereditary Spastic Paraplegias caused by mutations in the SPG11 gene.